Does pharmacogenetic testing optimize antidepressant effectiveness in major depressive disorder? Data from a double-blind randomized controlled trial in a real-world clinical setting

Abstract Background Major depressive disorder (MDD) exhibits significant heterogeneity in treatment responses, necessitating multiple pharmacological trials to achieve therapeutic success. Pharmacogenetic (PGx) testing has emerged as a promising tool to personalize antidepressant (AD) treatments, th...

Повний опис

Бібліографічні деталі

Автори:	Alessandra Minelli, Stefano Barlati, Stefano Bignotti, Valentina Menesello, Gabriele Nibbio, Giulia Perusi, Alessia Muscarella, Lisa Buson, Ughetta Bosco Umbertino, Paolo Martini, Rosana Carvalho Silva, Edoardo Spina, Giovanni Battista Tura, Antonio Vita, Massimo Gennarelli
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Cambridge University Press 2025-01-01
Серія:	European Psychiatry
Предмети:	antidepressant treatment depression genetics pharmacogenetic testing randomized controlled trial
Онлайн доступ:	https://www.cambridge.org/core/product/identifier/S0924933825101326/type/journal_article
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!